A 52-Year-Old Man With Ecchymotic Leg Ulcers

Seema Walvekar, MD; Jessica L. Johnson, PharmD, BCPS; Emily Kauffman, DO; Rachna Jetly, MD; Bennett P. deBoisblanc, MD, FCP, FACC, FCCM

CASE PRESENTATION

A 52-year-old man presented to the emergency department with a one-day history of pain and bluish discoloration of the tips of the great toes of both his feet that rapidly progressed to worsening pain, swelling, and discoloration of both feet and legs. His past medical history was significant for many years of heavy alcohol use and an episode of unprovoked venous thromboembolism two months prior to presentation. At that time, he was found to be heterozygous for Factor V Leiden mutation. After initial anticoagulation with fondaparinux, he was started on warfarin 7.5 mg daily. A removable inferior vena cava filter was placed for unclear indications. In the emergency department, his review of systems was remarkable for a one-day history of melena with hematemesis. On subsequent questioning, he admitted to only sporadic compliance with his warfarin therapy and laboratory monitoring.

On physical examination, the patient was noted to have hemorrhagic bullae of the skin of the anterior pretibial surfaces of both legs (Figure 1). His laboratory data was significant for a hemoglobin of 3 g/dl (13.5-17.5 gm/dl), white blood cell count 28,000/mm3 (normal 4.5,000-11,000/mm3), platelet count 54,000/mm3 (normal 130,000-400,000/mm3), International Normalized Ratio (INR) > 9.5 (normal 0.9-1.1) quantitative D-dimer >5000 ng/mL(normal <200 ng/dl), and fibrinogen 311 mg/dL (normal 200-600 mg/dl). No gastrointestinal source of bleeding was identified on esophagogastroduodenoscopy. Ultrasound demonstrated bilateral popliteal thrombosis. Within hours, hemorrhagic bullae formed over both pretibial areas, and purpura began to appear on his upper extremities. He was transfused with packed red blood cells and fresh frozen plasma. Therapy for presumed warfarin-induced skin necrosis (WISN), i.e. heparin or recombinant activated protein C infusion, was withheld due to the elevated INR, thrombocytopenia, and a low hemoglobin level.

Skin punch biopsy of the purpura over his legs showed separation of the stratum corneum, focal necrosis of acrosyrinx, and thrombosis of blood vessels throughout the dermis and subcutaneous tissue (Figure 2). There was no evidence of vasculitis. He ultimately developed limb gangrene, requiring bilateral above knee amputations.

DISCUSSION

Skin necrosis is a rare complication of anticoagulation with warfarin that results from extensive thrombotic...
occlusion of small vessels, resulting in large areas of dermal necrosis requiring debridement or limb amputation. Clinical mimics of WISN include: necrotizing fasciitis, purpura fulminans, calciphylaxis, cryoglobulinemia, cholesterol embolization, heparin-induced skin necrosis, and lupus anticoagulant-associated skin necrosis. These conditions must be ruled out to consider a diagnosis of WISN.

The most plausible hypothesis explaining WISN is that initiation of warfarin treatment causes a transient imbalance of pro- and anti-coagulant factors that favors thrombosis. Within the first 24 hours of an initial dose, warfarin reduces the anticoagulant activity of protein C by almost 50%. However, the activity of Vitamin K-dependent procoagulant factors is inhibited by warfarin at a much slower rate due to the longer half-lives of these factors (Table). The slower clearance of the procoagulant factors leads to transient hypercoagulability and the potential for thrombosis during this early phase of warfarin therapy. This mechanism is more pronounced when higher doses of warfarin are used or when a patient has a genetic or acquired protein C deficiency. Heparin bridging is used to inhibit procoagulant cloting factors and thus, to prevent WISN in patients with protein C deficiency until this procoagulant factors are cleared, typically by day five of therapy.

WISN has an estimated incidence of 0.01-0.1% in the general population of patients receiving oral Vitamin K antagonists. However, as many as one-third of these cases occur in patients who are heterozygous for protein C or S deficiency. WISN has not only been associated with acquired and hereditary deficiencies of proteins C and S, but also with activated protein C (APC) resistance secondary to Factor V Leiden mutation.

APC downregulates the production of thrombin by enzymatically deactivating clotting factors Va and VIIIa. APC resistance is a common risk factor for thrombosis, and between 20% and 60% of thrombophilic patients suffer from some form of APC resistance. The most common point mutation leading to APC resistance among Caucasians is at the R506Q site of Factor Va (FVa), known as the Factor V Leiden mutation.

Procoagulant FVa is deactivated by APC with an initial cleavage of the FVa peptide at the Arg506 position, followed by a second cleavage at Arg306. The Factor V Leiden R506Q point mutation, a substitution of arginine with glutamine, prevents cleavage at that position by APC. Although the mutant FVa can be inactivated by cleavage at Arg306, this cleavage is tenfold slower without prior cleavage at Arg506. Once cleaved at Arg506 by APC, deactivated FV functions as a cofactor in the APC-mediated degradation of Factor VIIIa. Individuals with Factor V Leiden mutation therefore have decreased deactivation of both FVa and F VIIIa and increased risk of thrombosis.

Individuals who are heterozygous for the Factor V

---

**Table: Half-life of Vitamin K-dependent clotting factors**

<table>
<thead>
<tr>
<th>Clotting Factor</th>
<th>Half-life</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein C</td>
<td>8 hours</td>
</tr>
<tr>
<td>Factor IX</td>
<td>24 hours</td>
</tr>
<tr>
<td>Factor X</td>
<td>48 hours</td>
</tr>
<tr>
<td>Factor II</td>
<td>2-5 days</td>
</tr>
<tr>
<td>Factor IV</td>
<td>1-6 days</td>
</tr>
<tr>
<td>Protein S</td>
<td>42 hours</td>
</tr>
</tbody>
</table>

---

**Figure 2:** Photomicrograph of a skin punch biopsy demonstrating thrombosis of blood vessels (arrows) throughout the dermis and subcutaneous tissue.
Leiden mutation carry a risk of venous thrombosis five to seven times higher than that of the general population; homozygous subjects have a risk 80 times higher. The incidence of Factor V Leiden mutation among the general Caucasian population is 0-8%, but up to 60% of patients with venous thromboembolism may test positive for Factor V Leiden mutation.9,11

Approximately 95% of patients who are heterozygous for Factor V Leiden mutation at the chromosome R506Q demonstrate APC resistance.8 Additional sources of APC resistance include other point mutations of Factor V, spontaneous generation of auto-antibodies targeting Factor V, and dysfunction or deficiency of APC cofactors, including protein S.

CASE SUMMARY

Our patient was predisposed to developing WISN. He was heterozygous for Factor V Leiden mutation at the R506Q position, increasing his risk of thrombosis. Patients with Factor V Leiden mutation are at increased risk of WISN, particularly when warfarin is initiated in high doses or without heparin bridging. Our patient admitted to intermittent compliance to prescribed therapy and monitoring. He stopped and started high-dose warfarin several times without monitoring or heparin bridging. He had no evidence of infection, no heparin use, no lupus anticoagulant, and no serum cryoglobulins. His biopsy showed characteristic intravascular thrombosis of small cutaneous vessels. Based on his history, laboratory data, histopathology, and that he was heterozygous for Factor V Leiden mutation, we confirmed the diagnosis of WISN.

Alcoholism also contributed to the development of WISN in our patient. Acute alcohol ingestion, as in binge drinking, impairs hepatic metabolism of warfarin and increases the effective anticoagulant dose. Patients with Factor V Leiden mutation requiring anticoagulation with warfarin should receive extensive counseling regarding alcohol use and the risk of re-initiating therapy after self-discontinuation without heparin bridging. Consideration should be given to alternative oral anticoagulation (rivaroxaban, dabigatran) for patients with risk factors for WISN.

REFERENCES


Drs. Walvekar and Kaufman are with the Department of Internal Medicine at the Louisiana State University Health Sciences Center in New Orleans. Dr. Kaufman is a Resident there. Dr. Johnson is a Clinical Assistant Professor at Xavier University of Louisiana College of Pharmacy and is affiliated with Interim Louisiana Hospital, Medical Intensive Care Unit at LSUHSC-New Orleans. Dr. Jetly is with the Department of Pathology at LSUHSC-New Orleans. Dr. deBoisblanc is a Professor of Medicine and Pathology and is affiliated with the Pulmonary section of Critical Care at LSUHSC-New Orleans.